Industry

Cloudbreak Pharma Launches New Website to Support US Expansion and Highlight Ophthalmic Pipeline

Eyewire+5h ago2 min read

Key Takeaways Cloudbreak Pharma launched a new website to support its US expansion and increase visibility of its ophthalmic drug pipeline Its lead candidate, CBT-001 for pterygium, is in mid-phase 3 trials, targeting a condition with no FDA-approved drug treatments A second therapy, CBT-004 for pinguecula, is entering phase 3 Cloudbreak Pharma has announced the launch of its new corporate website as part of a broader strategy to expand its presence in the United States and raise awareness of its pipeline of eye disease treatments. The website, www.cloudbreakpharma.com, is designed to serve as a central hub for patients, healthcare professionals, investors, and potential partners seeking information about the company’s therapies targeting front-of-the-eye diseases. The launch comes as Cloudbreak lead drug candidate, CBT-001, approaches a key data readout in mid-phase 3 clinical trials. The investigational eye drop is being developed to treat pterygium, a potentially sight-threatening condition affecting an estimated 15 million people in the United States. “There are currently no FDA-approved disease-modifying treatments for pterygium,” said Abu Abraham, MD, Chief Medical Officer of Cloudbreak. “With our MKI platform targeting the root causes of disease rather than just symptoms, we believe we have the potential to significantly improve outcomes for millions of patients.” Pterygium is typically managed with symptomatic treatments such as artificial tears or anti-inflammatory drugs, while more severe cases may require surgery—an option chosen by about 100,000 patients annually in the US. In addition to CBT-001, Cloudbreak is advancing CBT-004, another eye drop therapy that is entering phase 3 trials for the treatment of pinguecula, a common ocular condition affecting approximately 50 million Americans, particularly older adults. Pinguecula, characterized by a yellowish growth on the eye’s surface, currently lacks FDA-approved pharmacological treatments. Existing therapies primarily address symptoms rather than the underlying disease process, according to Cloudbreak. Both CBT-001 and CBT-004 are based on Cloudbreak’s proprietary Multi-Kinase Inhibitor (MKI) platform, which targets multiple receptor tyrosine kinases involved in disease progression. The company believes this approach could offer a first-in-class solution for conditions with significant unmet medical needs.

Read full article on Eyewire+

AI Summary

Quick Take

Cloudbreak Pharma has launched a new corporate website to anchor its U.S. expansion as it advances two first-in-class ophthalmic candidates into late-stage trials. The pipeline is led by CBT-001, a multi-kinase inhibitor for pterygium currently in Phase 3, and CBT-004, which is entering Phase 3 for the treatment of pinguecula.

Why It Matters

For decades, pterygium and pinguecula have been managed reactively with lubricants or steroids, with surgery as the only definitive—yet often recurring—intervention. Cloudbreak’s MKI platform represents a shift toward disease-modifying pharmacological therapy by targeting the underlying receptor tyrosine kinases responsible for lesion growth. If successful, these eye drops could provide a non-surgical alternative for the 15 million Americans with pterygium and the 50 million with pinguecula, addressing a massive gap in the current ophthalmic pharmacopeia where no FDA-approved drugs currently exist.

Key Details

CBT-001 is a topical eye drop currently in mid-Phase 3 clinical trials for the treatment of pterygium, with a key data readout approaching.
CBT-004 is entering Phase 3 trials for pinguecula, a condition affecting approximately 50 million Americans, particularly older adults.
Both candidates utilize a proprietary Multi-Kinase Inhibitor (MKI) platform designed to target the root biological causes of ocular surface growths rather than just managing symptoms.
Approximately 100,000 patients in the U.S. undergo surgery for pterygium annually, highlighting the significant unmet need for medical management.
The new corporate website serves as a central hub for clinical data and pipeline updates as the company scales its U.S. presence.

Practice Implications

Clinicians should monitor the upcoming Phase 3 data for CBT-001, as a successful readout could introduce the first pharmacological option to arrest pterygium progression before surgical intervention is required. For the high volume of patients with pinguecula who are currently limited to artificial tears, the development of CBT-004 may eventually offer a targeted treatment to address the underlying lesion and prevent progression to pterygium.

Who's Affected

OphthalmologistsOptometristsCornea SpecialistsOcular Surface Specialists

What's Next

Cloudbreak is approaching a key data readout for the CBT-001 Phase 3 trial in pterygium. Simultaneously, the company is moving CBT-004 into Phase 3 trials, marking a significant step toward potential regulatory filings for both common ocular surface conditions.

Evidence StrengthModerate

AI-generated summary — always read the original source for full context

Discussion

No comments yet. Be the first to share your thoughts.